EGFR靶向药物个体化治疗转移性结直肠癌的研究进展

Research progress in individualized treatment of metastatic colorectal cancer with EGFR-targeted drugs

靶向表皮生长因子受体(epidermal growth factor receptor,EGFR)单抗目前已成为晚期结直肠癌治疗的一个突破,对此类药物相关基因的研究也开创了结直肠癌个体化治疗的先河。EGFR信号转导系统中EGFR基因、配体以及下游的KRAS,BRAF和PIK3CA基因一直都是研究的热点。本文就EGFR靶向药物疗效相关预测因子的研究现状做一综述。

Epidermal growth factor receptor （EGFR） monoclonal antibody has become a breakthrough in the treatment of advanced colorectal cancer. Researches on the drug-related genes also created a precedent for individualized treatment of colorectal cancer. Recently, lots of bio-markers have been reported, such as EGFR ligands and KRAS, BRAF and PIK3CA in the downstream of the EGFR signal pathway. The objective of this paper is to in- troduce the bio-marker researches of EGFR monoclonal antibody.